YOLFTbeta
60

Beijing Konruns Pharmaceutical Co Ltd

603590 · SHG · Healthcare / Biotechnology

24.46CNY-0.66 (-2.63%)

Price History

Full chart

Market Stats

Previous Close25.12
Open25.02
Day Range24.34 – 25.24
52-Week Range27.33 – 54.86
Volume1.68M
Market Cap5.18B
P/E (TTM)30.01
Forward P/E0.00
EPS1.07
Dividend Yield1.09%
Beta0.40
50-Day Avg30.77
200-Day Avg35.69

About

Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon halys hemocoagulase under Suling trade name. It is also involved in the development of drug candidates, including ZY5301 that is in phase 3 clinical trials for the treatment of chronic pelvic pain in sequelae of pelvic inflammatory disease; and KC1036, which is in phase 2 clinical trial for the treatment of solid tumors. The company was founded in 2003 and is headquartered in Beijing, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Zhanqi Niu
  • Employees793
  • HeadquartersBuilding 3, No. 7 Science Park Road, Beijing, China, 102206, China
  • Websitehttps://www.konruns.cn

Leadership

  • Mr. Zhanqi NiuPresident & Director · b. 1967
  • Mr. Xiaohan LiuCFO & Director · b. 1988
  • Jing WangAccounting Supervisor
  • Mr. Xiao Dong HuangSecretary to the Board · b. 1971

Financials

Income Statement

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue250.36M303.69M436.15M346.23M590.58M973.16M1.07B808.64M809.78M866.73M920.01M825.40M915.12M
Growth (%)-+21.30%+43.62%-20.62%+70.58%+64.78%+9.53%-24.14%+0.14%+7.03%+6.15%-10.28%+10.87%
Cost of Revenue29.79M35.58M41.22M38.18M44.97M50.05M57.66M59.25M105.76M126.65M101.05M86.26M92.25M
Gross Profit568.60M508.91M394.93M308.04M545.61M923.12M1.01B749.40M704.02M740.07M818.96M739.14M822.87M
Gross Margin227.11%167.57%90.55%88.97%92.39%94.86%94.59%92.67%86.94%85.39%89.02%89.55%89.92%
Operating Expense455.03M364.09M191.18M100.20M-11.50M623.08M708.75M539.17M511.73M599.37M675.68M700.05M624.29M
Operating Income113.56M144.82M203.75M207.84M557.11M300.04M299.51M210.22M192.29M140.70M143.28M39.09M198.58M
Operating Margin45.36%47.69%46.72%60.03%94.33%30.83%28.10%26.00%23.75%16.23%15.57%4.74%21.70%
EBITDA139.35M186.30M189.78M188.15M207.39M203.59M240.24M141.71M144.29M151.54M165.35M146.73M233.49M
EBITDA Margin55.66%61.34%43.51%54.34%35.12%20.92%22.54%17.52%17.82%17.48%17.97%17.78%25.51%
Net Income118.44M175.90M195.25M191.65M478.82M263.93M266.08M183.36M147.99M101.49M150.45M42.22M165.97M
Net Income Margin47.31%57.92%44.77%55.36%81.08%27.12%24.96%22.67%18.27%11.71%16.35%5.11%18.14%
R&D35.92M39.60M38.73M38.39M32.17M80.25M108.78M93.11M102.27M86.78M94.91M54.94M51.86M
R&D as % of Total Revenue14.35%13.04%8.88%11.09%5.45%8.25%10.21%11.51%12.63%10.01%10.32%6.66%5.67%
Interest Expense331.46K20.30K19.92K12.95K14.04K17.69K27.21K418.42K1.49M913.96K2.39M6.21M7.53M
Interest Expense % of Total Revenue0.13%0.01%0.00%0.00%0.00%0.00%0.00%0.05%0.18%0.11%0.26%0.75%0.82%

Balance Sheet

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets515.13M665.04M845.80M1.02B1.67B2.92B3.17B3.79B3.37B3.42B3.78B3.92B4.09B
Total Liabilities201.68M177.02M162.53M147.37M318.93M439.48M445.84M701.72M240.74M234.68M418.44M493.52M598.51M
Total Equity312.02M488.02M683.27M874.92M1.36B2.48B2.73B3.08B2.89B2.93B3.06B3.14B3.21B
Cash112.84M39.93M34.67M214.04M542.73M1.69B1.80B1.35B599.08M345.25M230.20M189.98M332.57M
Total Debt-------24.47M18.62M12.42M140.71M201.60M-
Net Debt-112.84M-39.93M-34.67M-214.04M-542.73M-1.69B-1.80B-1.32B-580.46M-332.83M-80.42M11.62M-

Cash Flow

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow163.72M130.98M191.80M148.26M270.49M263.11M262.00M58.41M70.91M119.69M199.35M172.25M115.68M
Investing Cash Flow-98.52M-203.88M-175.23M35.66M62.62M-7.37M-303.69M-420.83M-642.45M-324.51M-447.72M-198.40M-
Financing Cash Flow6.79M--22.75M-10.23M-2.52M891.35M-80.00M-93.04M57.76M-56.89M143.62M-8.27M-
Capital Expenditure58.17M34.20M45.09M178.67M33.73M16.85M18.89M50.37M164.65M96.31M100.91M104.02M53.45M
Free Cash Flow105.55M96.77M146.72M-30.41M236.76M246.26M243.12M8.03M-93.74M23.38M98.44M68.22M62.23M
Dividends Paid12.38M---80.00M80.00M80.00M80.00M55.18M46.95M34.95M53.49M102.39M
FCF to OCF64.47%73.89%76.49%-20.51%87.53%93.60%92.79%13.75%-132.19%19.53%49.38%39.61%53.79%
Dividend Paid to FCF11.72%---33.79%32.49%32.91%995.98%-58.87%200.81%35.50%78.41%164.54%

Earnings

Report DateSep 30, 2018Dec 31, 2018Apr 29, 2019Aug 27, 2019Oct 29, 2019Dec 31, 2019Apr 27, 2020Jul 27, 2020Oct 19, 2020Mar 22, 2021Apr 28, 2021Aug 23, 2021Oct 25, 2021Dec 31, 2021Apr 22, 2022Aug 1, 2022Oct 25, 2022Dec 31, 2022Apr 25, 2023Jul 31, 2023
EPS Estimate--------------------
EPS Actual0.350.670.310.630.340.390.390.450.240.260.410.220.240.070.300.230.14-0.010.160.43
Surprise--------------------
Timing------After-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hours-Pre-marketPre-marketPre-market-Pre-marketPre-market

Key Statistics & Ratios

Market Cap5.18B
Enterprise Value4.31B
Trailing P/E30.01
Forward P/E0.00
Price / Sales5.65
Price / Book1.49
EPS1.07
Book Value20.28
Revenue (TTM)917.05M
Gross Profit (TTM)822.88M
EBITDA217.27M
Profit Margin18.61%
Operating Margin21.65%
Return on Equity5.05%
Return on Assets2.90%
Shares Outstanding161.29M
Shares Float80.50M
Beta0.40
Dividend Yield1.09%
Dividend Rate0.35
Payout Ratio0.00%

Dividends

20231×
0.20Jul 7, 2023
20221×
0.30Jun 29, 2022
20211×
0.35May 31, 2021
20201×
0.50Jun 11, 2020
20191×
0.50Jun 3, 2019